Literature DB >> 12161471

Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.

Eleni V Dimaraki1, Craig A Jaffe, Roberta DeMott-Friberg, William F Chandler, Ariel L Barkan.   

Abstract

The biochemical diagnosis of acromegaly is conventionally based on elevated plasma GH levels that fail to suppress after an oral glucose load. We studied 16 newly diagnosed patients with acromegaly with normal mean plasma GH but elevated age and gender-adjusted plasma IGF-I concentrations (476 +/- 29 microg/liter, mean +/- SE). Plasma GH was sampled every 10 min for 24 h, and an oral glucose tolerance test was performed. The control group included 46 healthy subjects. All patients had 24-h mean GH values that overlapped with those of the healthy controls. Mean plasma GH was less than 2.5 microg/liter in 12 patients. Patients had higher 24-h nadir GH values than healthy controls (P < 0.001). During the oral glucose tolerance test, nadir plasma GH was less than 1 micro g/liter in eight patients. Plasma IGF-I normalized in 11 of 14 patients after transsphenoidal surgery. Four patients with normal IGF-I after transsphenoidal surgery were restudied. Mean and nadir GH decreased in all of them. In our experience in many patients with acromegaly, the diagnosis could be missed if only the existing GH-based criteria are used. Revised GH criteria in combination with plasma IGF-I should be used for the diagnosis and follow-up of acromegaly.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12161471     DOI: 10.1210/jcem.87.8.8658

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  50 in total

1.  Acromegaly: are new tests needed?

Authors:  Anna Spada
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

2.  Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly.

Authors:  Pamela U Freda; Carlos M Reyes; Abu T Nuruzzaman; Robert E Sundeen; Jeffrey N Bruce
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 3.  GH receptor antagonist: mechanism of action and clinical utility.

Authors:  Sowmya K Surya; Ariel L Barkan
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

4.  "Micromegaly": an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era.

Authors:  Laura B Butz; Stephen E Sullivan; William F Chandler; Ariel L Barkan
Journal:  Pituitary       Date:  2016-12       Impact factor: 4.107

5.  Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?

Authors:  R Cozzi; R Attanasio; S Grottoli; G Pagani; P Loli; V Gasco; A M Pedroncelli; M Montini; E Ghigo
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

Review 6.  Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.

Authors:  A Giustina; A Barkan; P Chanson; A Grossman; A Hoffman; E Ghigo; F Casanueva; A Colao; S Lamberts; M Sheppard; S Melmed
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

Review 7.  Pitfalls in the biochemical assessment of acromegaly.

Authors:  Pamela U Freda
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 8.  Somatostatin analogs in medical treatment of acromegaly.

Authors:  Michael S Racine; Ariel L Barkan
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

Review 9.  Management of acromegaly in Latin America: expert panel recommendations.

Authors:  Ariel Barkan; Marcello D Bronstein; Oscar D Bruno; Alejandro Cob; Ana Laura Espinosa-de-los-Monteros; Monica R Gadelha; Gloria Garavito; Mirtha Guitelman; Ruth Mangupli; Moisés Mercado; Lesly Portocarrero; Michael Sheppard
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

Review 10.  The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.

Authors:  Anne Klibanski; Shlomo Melmed; David R Clemmons; Annamaria Colao; Regina S Cunningham; Mark E Molitch; Aaron I Vinik; Daphne T Adelman; Karen J P Liebert
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.